Novartis (NYSE:NVS) Shares Unloaded Rep. Lisa C. McClain

Representative Lisa C. McClain (R-Michigan) recently sold shares of Novartis AG (NYSE:NVS). In a filing disclosed on November 21st, the Representative disclosed that they had sold between $1,001 and $15,000 in Novartis stock on October 31st. The trade occurred in the Representative’s “CHARLES SCHWAB 401K > SCHWAB 893” account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Alibaba Group (NYSE:BABA) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Coherent (NYSE:COHR) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Clorox (NYSE:CLX) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Northern Trust (NASDAQ:NTRS) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Honda Motor (NYSE:HMC) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Home BancShares (NYSE:HOMB) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Five Below (NASDAQ:FIVE) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Pure Storage (NYSE:PSTG) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of BHP Group (NYSE:BHP) on 10/31/2025.

Novartis Trading Up 0.1%

NYSE NVS opened at $130.44 on Thursday. The company has a market cap of $275.54 billion, a PE ratio of 17.82, a PEG ratio of 1.93 and a beta of 0.60. The company has a current ratio of 0.88, a quick ratio of 0.62 and a debt-to-equity ratio of 0.50. Novartis AG has a 12 month low of $96.06 and a 12 month high of $134.00. The stock has a 50 day moving average of $128.00 and a 200-day moving average of $122.30.

Novartis (NYSE:NVS) last issued its earnings results on Tuesday, October 28th. The company reported $2.25 earnings per share for the quarter, missing analysts’ consensus estimates of $2.26 by ($0.01). Novartis had a return on equity of 41.21% and a net margin of 26.49%.The firm had revenue of $14.36 billion for the quarter, compared to analyst estimates of $13.70 billion. During the same quarter in the previous year, the firm posted $2.06 earnings per share. Novartis’s quarterly revenue was up 8.5% on a year-over-year basis. On average, equities research analysts anticipate that Novartis AG will post 8.45 EPS for the current fiscal year.

Institutional Investors Weigh In On Novartis

Institutional investors have recently made changes to their positions in the company. Dimensional Fund Advisors LP increased its stake in shares of Novartis by 5.2% during the first quarter. Dimensional Fund Advisors LP now owns 8,606,724 shares of the company’s stock worth $959,535,000 after purchasing an additional 422,869 shares during the period. Fisher Asset Management LLC grew its holdings in Novartis by 1.7% in the 3rd quarter. Fisher Asset Management LLC now owns 7,239,366 shares of the company’s stock valued at $928,376,000 after buying an additional 117,952 shares in the last quarter. Loomis Sayles & Co. L P increased its position in Novartis by 1.4% during the 2nd quarter. Loomis Sayles & Co. L P now owns 5,581,576 shares of the company’s stock worth $675,427,000 after buying an additional 78,483 shares during the period. Bank of America Corp DE lifted its holdings in shares of Novartis by 1.7% during the third quarter. Bank of America Corp DE now owns 4,605,878 shares of the company’s stock worth $590,658,000 after buying an additional 78,390 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of Novartis by 60.3% during the first quarter. Goldman Sachs Group Inc. now owns 3,660,485 shares of the company’s stock worth $408,071,000 after buying an additional 1,377,252 shares in the last quarter. Institutional investors own 13.12% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on NVS shares. Cfra set a $126.00 price objective on shares of Novartis and gave the stock a “hold” rating in a research note on Wednesday, October 29th. Morgan Stanley raised Novartis from an “equal weight” rating to an “overweight” rating in a research report on Friday, October 31st. The Goldman Sachs Group reaffirmed a “sell” rating and issued a $118.00 price objective (down from $119.00) on shares of Novartis in a research report on Friday, September 12th. Jefferies Financial Group reissued a “hold” rating on shares of Novartis in a report on Monday, October 27th. Finally, Weiss Ratings restated a “buy (b)” rating on shares of Novartis in a research note on Thursday, November 20th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, six have given a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $122.33.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.